Gastrointestinal events

1 paper1 finding

Humans1

Associations

1

Older age

downin humans1RR 0.8

1 study

Older age lowers the risk of gastrointestinal events in humans (RR 0.80; 95% CI 0.76 - 0.84).
“Paradoxically, they had lower risks for endocrine (RR 0.86; 95% CI 0.83 - 0.89) and gastrointestinal (RR 0.80; 95% CI 0.76 - 0.84) events.”
Humanscancer patients initiating ICIs
Differential Toxicity of Immune Checkpoint Inhibitors in Older Adults: A Large-Scale, Propensity Score-Matched Real-World Analysis
Cancer investigationApr 16, 2026

Latest

13 in 12 months

HealthcareYesterday

Real-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy Study

Cross-sectional study of 531 peopleGLP-1 receptor agonists

Endocrinology, Diabetes & MetabolismSep 19

Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan

Non-randomized trial in 259 peopleLiraglutide

BMC Endocrine DisordersSep 17

Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis

Meta-analysis of randomized trialsOrforglipron

Obesity Research & Clinical PracticeSep 15

A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan

Cohort study of 41 peopleGLP-1 receptor agonists

CureusSep 13

Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review

Systematic review of studies in peopleTirzepatide

CureusSep 1

Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes

Systematic review of studies in peopleObesity

Signal Transduction and Targeted TherapyAug 14

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial

Randomized trial in 250 peopleObesity

NutrientsJun 12

GLP-1 Receptor Agonists in the Rehabilitation of Patients with Heart Failure: Mechanisms, Clinical Evidence, and Future Perspectives

ReviewGLP-1 receptor agonists

ADA Scientific Sessions 2026 AbstractJun 6

Safety, Pharmacokinetics, and Weight Loss Effects of the Oral GLP-1/GIP Dual Agonist BGM0504 in Healthy and Overweight or Obese Adults: A Phase 1 Multiple-Ascending Dose Study

Randomized trial in 75 peopleOverweight

ADA Scientific Sessions 2026 AbstractJun 6

Efficacy and Safety of Extended-Interval PG-102, a GLP-1/GLP-2 Bispecific Agonist, in Adults with Type 2 Diabetes

Randomized trial in 48 peopleType 2 diabetes